Gauvreau, Gail M, Arm, Jonathan P, Boulet, Louis-Philippe, Leigh, Richard, Cockcroft, Donald W, Davis, Beth E, Mayers, Irvin, FitzGerald, J Mark, Dahlen, Barbro, Killian, Kieran J, Laviolette, Michel, Carlsten, Christopher, Lazarinis, Nikolaos, Watson, Richard M, Milot, Joanne, Swystun, Veronica, Bowen, Miranda, Hui, Linda, Lantz, Ann-Sofie, Meiser, Karin, Maahs, Suzanne, Lowe, Philip J, Skerjanec, Andrej, Drollmann, Anton and O'Byrne, Paul M (2016) Efficacy and safety of multiple doses of QGE031 (ligelizumab) versus omalizumab and placebo in inhibiting allergen-induced early asthmatic responses. The Journal of allergy and clinical immunology, in pre (in pre). 00-00. ISSN 1097-6825

Abstract

Omalizumab is an established anti-IgE therapy for the treatment of allergic diseases that prevents IgE from binding to its receptor. QGE031 is an investigational anti-IgE antibody that binds IgE with higher affinity than omalizumab.

Item Type:	Article
Date Deposited:	16 Sep 2016 00:45
Last Modified:	16 Sep 2016 00:45
URI:	https://oak.novartis.com/id/eprint/30938